News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
376,419 Results
Type
Article (14747)
Company Profile (116)
Press Release (361551)
Multimedia
Podcasts (50)
Webinars (9)
Section
Business (112785)
Career Advice (457)
Deals (18656)
Drug Delivery (41)
Drug Development (31258)
Employer Resources (51)
FDA (8839)
Job Trends (7696)
News (173045)
Policy (12400)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Standard (3)
Academia (1332)
Accelerated approval (10)
Allergies (73)
Alliances (34933)
ALS (43)
Alzheimer's disease (630)
Antibody-drug conjugate (ADC) (180)
Approvals (9044)
Artificial intelligence (448)
Autoimmune disease (65)
Automation (31)
Bankruptcy (131)
Best Places to Work (6520)
BIOSECURE Act (7)
Biosimilars (31)
Biotechnology (86)
Bladder cancer (62)
Brain cancer (27)
Breast cancer (263)
Cancer (2198)
Cardiovascular disease (150)
Career advice (416)
Career pathing (9)
CAR-T (203)
CDC (8)
Cell therapy (494)
Cervical cancer (21)
Clinical research (25879)
Collaboration (1244)
Compensation (233)
Complete response letters (8)
COVID-19 (1225)
CRISPR (85)
C-suite (487)
Cystic fibrosis (60)
Data (2649)
Decentralized trials (1)
Denatured (26)
Depression (43)
Diabetes (212)
Diagnostics (5152)
Digital health (37)
Diversity (7)
Diversity, equity & inclusion (9)
Drug discovery (169)
Drug pricing (19)
Drug shortages (4)
Duchenne muscular dystrophy (88)
Earnings (40545)
Editorial (9)
Employer branding (8)
Employer resources (46)
Events (53428)
Executive appointments (553)
FDA (10454)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (5)
Frontotemporal dementia (8)
Funding (901)
Gene editing (171)
Generative AI (39)
Gene therapy (347)
GLP-1 (304)
Government (1280)
Grass and pollen (3)
Guidances (220)
Healthcare (9918)
HIV (24)
Huntington's disease (13)
IgA nephropathy (26)
Immunology and inflammation (70)
Immuno-oncology (19)
Indications (50)
Infectious disease (1368)
Inflammatory bowel disease (81)
Inflation Reduction Act (5)
Influenza (74)
Intellectual property (151)
Interviews (52)
IPO (8061)
IRA (10)
Job creations (1438)
Job search strategy (363)
JPM (20)
Kidney cancer (6)
Labor market (24)
Layoffs (131)
Leadership (7)
Legal (2535)
Liver cancer (43)
Longevity (6)
Lung cancer (248)
Lymphoma (174)
Machine learning (34)
Management (18)
Manufacturing (528)
MASH (36)
Medical device (11844)
Medtech (11893)
Mergers & acquisitions (11234)
Metabolic disorders (405)
Multiple sclerosis (62)
NASH (3)
Neurodegenerative disease (122)
Neuropsychiatric disorders (19)
Neuroscience (1086)
NextGen: Class of 2026 (3537)
Non-profit (1534)
Now hiring (15)
Obesity (144)
Opinion (97)
Ovarian cancer (93)
Pain (105)
Pancreatic cancer (101)
Parkinson's disease (118)
Partnered (20)
Patents (302)
Patient recruitment (246)
Peanut (31)
People (33689)
Pharmaceutical (18)
Pharmacy benefit managers (3)
Phase 1 (9520)
Phase 2 (11622)
Phase 3 (7552)
Pipeline (2596)
Policy (59)
Postmarket research (502)
Preclinical (4283)
Press Release (66)
Prostate cancer (96)
Psychedelics (6)
Radiopharmaceuticals (178)
Rare diseases (303)
Real estate (3399)
Recruiting (23)
Regulatory (10390)
Reports (20)
Research institute (1301)
Resumes & cover letters (69)
Rett syndrome (21)
RNA editing (9)
RSV (40)
Schizophrenia (32)
Series A (163)
Series B (112)
Service/supplier (6)
Sickle cell disease (32)
Special edition (1)
Spinal muscular atrophy (60)
Sponsored (20)
Startups (2528)
State (2)
Stomach cancer (2)
Supply chain (48)
Tariffs (10)
The Weekly (23)
Vaccines (503)
Venture capital (43)
Weight loss (51)
Women's health (47)
Worklife (2)
Date
Today (74)
Last 7 days (310)
Last 30 days (1102)
Last 365 days (14720)
2026 (1517)
2025 (15032)
2024 (18709)
2023 (22098)
2022 (30815)
2021 (32512)
2020 (30537)
2019 (25793)
2018 (19458)
2017 (18871)
2016 (17761)
2015 (20560)
2014 (15177)
2013 (12742)
2012 (13782)
2011 (14066)
2010 (12826)
Location
Africa (325)
Alabama (69)
Alaska (6)
Arizona (178)
Arkansas (10)
Asia (24900)
Australia (4315)
California (5307)
Canada (1672)
China (550)
Colorado (286)
Connecticut (237)
Delaware (107)
Europe (50957)
Florida (913)
Georgia (219)
Hawaii (2)
Idaho (33)
Illinois (474)
India (34)
Indiana (265)
Iowa (8)
Japan (274)
Kansas (101)
Kentucky (15)
Louisiana (18)
Maine (22)
Maryland (719)
Massachusetts (3566)
Michigan (275)
Minnesota (408)
Mississippi (4)
Missouri (99)
Montana (27)
Nebraska (15)
Nevada (51)
New Hampshire (83)
New Jersey (1567)
New Mexico (18)
New York (1424)
North Carolina (765)
North Dakota (9)
Northern California (2251)
Ohio (169)
Oklahoma (16)
Oregon (24)
Pennsylvania (1012)
Puerto Rico (19)
Rhode Island (34)
South America (512)
South Carolina (60)
South Dakota (1)
Southern California (2274)
Tennessee (104)
Texas (880)
United States (19801)
Utah (194)
Vermont (1)
Virginia (92)
Washington D.C. (18)
Washington State (502)
West Virginia (3)
Wisconsin (88)
Wyoming (1)
376,419 Results for "liquidia technologies".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Regulatory
Liquidia Misses Full Approval for Pulmonary Hypertension Drug as Competitor Retains Market Exclusivity
The FDA on Monday only granted Liquidia’s Yutrepia tentative approval, keeping it off the U.S. market until after rival United Therapeutics’ exclusivity expires in May 2025.
August 19, 2024
·
2 min read
·
Tristan Manalac
Policy
FDA Misses PDUFA Date for Liquidia’s NDA for Inhaled Blood Pressure Drug
After missing its Jan. 24 PDUFA date, the regulator has extended its review period but has not issued a new decision timeframe or requested additional data, Liquidia announced Thursday.
January 25, 2024
·
1 min read
·
Kate Goodwin
Bio NC
Liquidia Corporation to Present at BofA Securities Health Care Conference 2024
Liquidia Corporation announced that Michael Kaseta, chief operating officer and chief financial officer, will provide an update on the company’s business during a fireside chat at the BofA Securities Health Care Conference 2024 on Tuesday, May 14, 2024, beginning at 5:00 p.m.
May 7, 2024
·
1 min read
Regulatory
6 Biotechs With a Shot at the FDA’s Platform Technology Designation
After revoking Sarepta’s award in July and awarding one to Krystal last month, the FDA’s platform technology designation program appears to be back on track. These six biotechs could be on the regulator’s radar.
November 21, 2025
·
9 min read
·
Tristan Manalac
Press Releases
Zelluna promotes Emilie Gauthy to Chief Technology Officer
February 3, 2026
·
2 min read
Press Releases
Avant Technologies Highlights the Critical Role of Cell Encapsulation Technology in Revolutionizing Diabetes Treatment
December 17, 2025
·
5 min read
Press Releases
Artis BioSolutions Announces Agreement to Acquire Syngoi Technologies to Deliver Next Generation Solutions for Synthetic DNA Technology
January 6, 2026
·
4 min read
Policy
United Therapeutics Pursues New Claims For Trade Secret Misappropriation Against Liquidia
United Therapeutics Corporation (Nasdaq: UTHR) announced today that it is pursuing additional claims for trade secret misappropriation against Liquidia Technologies, Inc.
June 7, 2021
·
4 min read
Press Releases
Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer
February 3, 2026
·
6 min read
Press Releases
DBV Technologies to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit
February 10, 2026
·
2 min read
1 of 37,642
Next
